Prosecution Insights
Last updated: October 25, 2026
Application No. 17/635,029

METHOD FOR PRIMING AN EXTRACORPOREAL BLOOD CIRCUIT OF AN APPARATUS FOR EXTRACORPOREAL TREATMENT OF BLOOD AND APPARATUS FOR EXTRACORPOREAL TREATMENT OF BLOOD

Non-Final OA §103§112
Filed
Feb 14, 2022
Priority
Aug 19, 2019 — EU 19192317.6 +1 more
Examiner
LE, QUYNH DAO
Art Unit
3781
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Gambro Lundia AB
OA Round
3 (Non-Final)
33%
Grant Probability
At Risk
3-4
OA Rounds
0m
Est. Remaining
45%
With Interview

Examiner Intelligence

Grants only 33% of cases
33%
Career Allowance Rate
16 granted / 48 resolved
-36.7% vs TC avg
Moderate +12% lift
Without
With
+12.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
44 currently pending
Career history
100
Total Applications
across all art units

Statute-Specific Performance

§101
2.3%
-37.7% vs TC avg
§103
62.9%
+22.9% vs TC avg
§102
14.4%
-25.6% vs TC avg
§112
18.3%
-21.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 48 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 01/20/2026 has been entered. Response to Amendment The amendments filed on 01/20/2026 has been entered. Claims 16, 20, 21, 22, 24, 25, and 30 have been amended; claims 36-42 have been added; claims 1-15, 27-28, and 32-35 have been cancelled. Accordingly, claims 16-26 and 29-31, and 36-42 are pending and under consideration. Response to Arguments Applicant’s arguments with respect to claim(s) 16 have been considered but are moot because the new ground of rejection does not rely on the same combination of references applied in the prior rejection of record for any teaching or matter specifically challenged in the argument. In light of further search and consideration, claim 16 is now rejected under 35 U.S.C. 103 as being unpatentable over Arzt et al. US 2017/0348474 A1 (previously cited) in view of Muller-Spanka et al. US 2011/0208107 A1 (previously cited) and Hogard et al. US 2015/0314055 A1 (previously cited), with new interpretation of Arzt regarding the second blood line section. Applicant's arguments filed on 01/20/2026 have been fully considered but they are not persuasive. In response to applicant's argument that the references fail to show certain features of the invention, it is noted that the features upon which applicant relies (i.e., membrane gas exchanger being completely filled with priming fluid) are not recited in the rejected claim(s). Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See In re Van Geuns, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993). In this instant case, claim set recited “filling the blood side of the membrane gas exchange and the second blood line section” (claim 1), which is broadly and reasonably interpreted as partial filling. See rejection of claims below. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 41 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. The limitations of claim 41 are substantially similar to those of claim 40, which fails to further limit the subject matter of the claim upon which it depends. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 16-18, 25, 26, 31, 36, 37, and 39 are rejected under 35 U.S.C. 103 as being unpatentable over Arzt et al. US 2017/0348474 A1 (previously cited, hereinafter Arzt) in view of Muller-Spanka et al. US 2011/0208107 A1 (newly cited, hereinafter Muller-Spanka) and Hogard et al. US 2015/0314055 A1 (newly cited, hereinafter Hogard). Regarding claim 16, Arzt discloses a method of priming an extracorporeal blood circuit of an apparatus for extracorporeal treatment of blood (Par. 21 – “A method is provided for preparing and venting in a device for extracorporeal blood treatment, such as a heart-lung machine… After the attachment of the filling liquid and the attachment of the table line, the filling procedure is started manually and then takes place fully automatically”), wherein the apparatus 1 (Fig. 5 – patient module 1) for extracorporeal treatment of blood (Par. 21 – “a device for extracorporeal blood treatment”) comprises: an extracorporeal blood circuit 15+EC (see annotated Fig. 5 below – venous line 15 and extracorporeal blood circuit “EC”; Examiner notes that table set 33 acts in place of a patient during filling, and is provided with venous attachment 32b and arterial attachment 32a, see Par. 63) comprising a first blood line section L1 (see annotated Fig. 5 below) and a second blood line section L2 (see annotated Fig. 5 below); a blood pump 6 (Fig. 5 – blood pump 6) configured to be coupled to a pump section (see annotated Fig. 5 below – pump section between the reservoir 2 and the oxygenator 3) of the extracorporeal blood circuit 15+EC (see annotated Fig. 5 below – the annotated pump section belongs within the extracorporeal circuit “EC”); a membrane gas exchanger 3 (Fig. 5 – oxygenator 3) operatively coupled to the extracorporeal blood circuit 15+EC (see annotated Fig. 5 below – the oxygenator is disposed within the extracorporeal circuit “EC”), wherein the membrane gas exchanger 3 (Fig. 5) comprises a blood side (Par. 59 – “the venous side of an oxygenator 3”, and Par. 60 – “an arterial attachment of the oxygenator 3”) in fluid communication with the blood circuit 15+EC (see annotated Fig. 5 below – it can be seen that the oxygenator 3 is connected to the blood pump 6, which is in fluid communication with the circuit “EC”, thus the venous side of oxygenator 3 is also in fluid communication with the circuit “EC”. The arterial side of oxygenator is in communication with circuit “EC” such that it connects with the filter 5) and a gas side (Par. 60 – “the oxygenator 3 also has attachments for an oxygen supply…”), wherein the blood side comprises a blood inlet (Par. 59 – “venous side of an oxygenator 3”; Fig. 5 - the left line that connects pump 6 to oxygenator 3) connected to the first blood line section L1 (see annotated Fig. 5 below – the annotated first blood line section L1 connects to the venous side/left side of the oxygenator 3) and a blood outlet (Par. 60 – “an arterial attachment of the oxygenator 3, a liquid line”; Fig. 5 – the right line that connects oxygenator 3 to filter 5) connected to the second blood line section L2 (see annotated Fig. 5 below – the annotated second blood line section L2 connects to the arterial side of the oxygenator 3); wherein the method of priming comprises: - feeding a priming fluid into the extracorporeal blood circuit 15+EC (see annotated Fig. 5 below, and Par. 71 – “The filling liquid from the filling liquid container 45… flows by gravity via the venous side of the system into the reservoir 2 and onwards into the blood pump 6 located at the lower end of the reservoir 2 and then onwards into the filter 5”) and into the blood side of the membrane gas exchanger 3 (Fig. 5 – arrows from filling liquid container 45 starts to flow into the reservoir 2, passes through the blood pump 6 and into the venous side of the oxygenator 3, since “blood pump 6… has… the tangential outlet 62 is connected to the venous side of an oxygenator 3” as discussed in Par. 59) at least until the priming fluid fills the blood side of the membrane gas exchanger 3 and the second blood line section L2 (see annotated Fig. 5 below) with the priming fluid while the gas side is filled with air (Par. 113 – “After the filling and venting procedure, the patient is attached as follows. The patient is made ready during the filling procedure… After the system has been filled, the table set filled with the system is separated (severed) at the middle and plugged without air inclusions onto the prepared needles and perfusion commenced”, which indicates that prior to filling and connecting to a patient, the oxygenator 3 has to still be filled with air, including the gas side, because filling liquid has yet to prime the apparatus); - after filling the blood side of the membrane gas exchanger 3 (Fig. 5) and the second blood line section L2 (Fig. 5) with the priming fluid (Par. 89 –“The filling liquid is conveyed from the reservoir 45 into the oxygenator 3 and onwards into the arterial filter 5”, wherein when the filling liquid reaches filter 5, it also has to fill the annotated blood line section L2), controlling release of air bubbles (Par. 69 – “controllable valve 21… in the venting line”) from blood flowing in the extracorporeal blood circuit 15+EC (see annotated Fig. 5 below and Par. 71 – circuit “EC” is equipped with valve 21 for venting the patient module) at a blood outlet (see annotated Fig. 5 below – blood outlet) of the membrane gas exchanger 3 (see annotated Fig. 5 below – at the blood outlet of oxygenator 3, the outlet is connected with the filter 5 and valve 21 for venting) by generating transitory pressurization step (Par. 70-71 – “close the first controllable valve 21 (HC1), which is opened after the start of the filling procedure for the venting line of the filter 5, and after the response of the upper filling level sensor 10 in the reservoir 2…”, the action of closing and opening valve 21 as the priming fluid is filled generates pressurization, results in “an air cushion is created”) in the priming fluid in the blood side of the membrane gas exchanger 3 (Fig. 5, and Par. 72 – “The air cushion damps the flow behaviour of the incoming filling liquid…”; Examiner contends that the actuation upon valve 21 results in pressurization of the priming fluid, which results in air cushion as discussed in Par. 72 of Arzt, and since the priming fluid exists within the oxygenator 3, pressurization indeed takes place in the blood side of the oxygenator 3) and the second blood line section L2 (Fig. 5, and Par. 83 – “The first controllable valve 21 HC1 is opened for the venting line of the filter 5”), wherein each transitory pressurization step (Par. 70-71) comprises selectively increasing pressure of the priming fluid in the blood side of the membrane gas exchanger 3 and the second blood line section L2 (Par. 71 – “close the first controllable valve 21 (HC1)…”, and Par. 72 – “an air cushion is created in the filter by the closed first controllable valve 21 (HC1) and the therefore closed venting line. The air cushion damps the flow behaviour of the incoming filling liquid”, wherein closing the valve and running the filling liquid to create an air cushion indicate a pressure build up) followed by selectively decreasing pressure of the priming fluid in the blood side of the membrane gas exchanger 3 and the second blood line section L2 (Par. 71 – “the first controllable valve 21 (HC1), which is opened after the start of the filling procedure for the venting line of the filter 5, and after the response of the upper filling level sensor 10 in the reservoir 2, in order to control the active filling of the filter 5”, wherein opening the valve relieve the pressure build up, thus decreasing the pressure), wherein generating transitory pressurization steps comprises: transiently restricting or occluding flow of the priming fluid (Par. 70 of Arzt– “The control unit, for filling and venting the patient module, is configured to close the first controllable valve 21 (HC1), which is opened after the start of the filling procedure for the venting line of the filter 5, and after the response of the upper filling level sensor 10 in the reservoir 2…”) in the second blood line section L2 (see annotated Fig. 5 below) downstream from the blood side of the membrane gas exchanger 3 (Fig. 5 – valve 21 is placed after the oxygenator 3 given the filling fluid flow direction) while operating the blood pump 6 (Fig. 5, and Par. 88-89 – “The arrangement of reservoir 2 and blood pump 6, namely below the maximum filling level of the reservoir 2, ensures that the blood pump 6 is filled by gravity and, in this way, there is always liquid in the blood pump 6 during the venting procedure. The blood pump 6 filled with filling liquid is operated at periodic intervals at a low speed, depending on design and delivery rate”) by controlling a flow restrictor 21 (Fig. 5) placed on the second blood line section L2 (see annotated Fig. 5 below). PNG media_image1.png 414 586 media_image1.png Greyscale PNG media_image2.png 570 786 media_image2.png Greyscale Annotated Fig. 5 of Arzt However, Arzt does not explicitly disclose a membrane gas exchanger to exchange gas with blood flowing in the extracorporeal blood circuit, and a gas permeable membrane separating the blood side and the gas side, and wherein the gas side comprises a gas inlet and gas outlet configured to ventilate gas; two or more transitory pressurization steps, while the gas side remains filled with air to inhibit the gas in the gas side from entering the blood side of the membrane gas exchanger through the gas permeable membrane, wherein each transitory pressurization step of the two or more transitory pressurization steps, and wherein successive pairs of the two or more transitory pressurization steps are separated from each other by a selected time interval. Muller-Spanka, in the same field of endeavor of cardiopulmonary apparatus (Title), teaches a gas permeable membrane (Par. 64 – “The oxygenator comprises a membrane”) separating the blood side and the gas side (the membrane of an oxygenator is known to separate the blood flow and the gas flow), and wherein the gas side (Fig. 5 – the bottom of oxygenator 64) comprises a gas inlet (Fig. 5 – the O2 inlet on the left of oxygenator 64) and gas outlet (Fig. 5 – the O2 outlet on the right of oxygenator 64) configured to ventilate gas (Fig. 5 – the inlet and outlet of oxygen are capable of ventilate gas). Hogard, in the same field of endeavor of method of automated priming sequences (Abstract), teaches two or more transitory pressurization steps (Par. 99 – “the pinch valves of the system can be periodically actuated to open and close the saline lines”, wherein as established above, opening and closing a valve can create pressure build up and pressure relief), and wherein successive pairs of the two or more transitory pressurization steps are separated from each other by a selected time interval (Par. 99 – “For example, the pinch valves can be opened and closed every 4-8 seconds to create a pulsing effect of the saline in the lines”; a pair of two or more transitory pressurization is interpreted to be ). Since Par. 60 of Arzt does disclose that “The oxygenator 3 also has attachments for an oxygen supply (not shown)…”, it would have been obvious for one of ordinary skill in the art before the effective filing date of the claimed invention to have recognized that the oxygen supply made to the oxygenator would create a gas-blood interface in the oxygenator, and this oxygenator is indeed intended to perform gas exchange given the disclosed oxygen supply. Furthermore, Par. 59-60 of Arzt also discuss that “The blood pump 6… has… the tangential outlet 62 is connected to the venous side of an oxygenator 3” and “The oxygenator 3 also has attachments for an oxygen supply”. Therefore, one of ordinary skill in the art would have the technological capability to realize that the cited paragraphs support the fact that both blood and oxygen are delivered within this oxygenator 3, so that oxygen gas can transfer into the extracorporeal blood. It would have been obvious for one of ordinary skill in the art before the effective filing date of the claimed invention to have modified the oxygenator of Arzt to further have the gas permeable membrane and gas inlet/outlet as taught by Muller-Spanka, since it is well-known within the field of oxygenator to have a membrane with gas delivery means to perform oxygenation of blood. Given that the membrane of Muller-Spanka is impermeable to air bubbles (Par. 64 of Muller-Spanka), air present in the oxygenator cannot pass through said membrane. Therefore, the limitation “after the priming fluid fills the blood side of the membrane gas exchanger and while the gas side remains filled with air to inhibit the gas in the gas side from entering the blood side of the membrane gas exchanger through the gas permeable membrane” is met because air in the gas side remains within the gas side given the impermeability of the membrane. Lastly, it would have been obvious for one of ordinary skill in the art before the effective filing date of the claimed invention to have modified the pressurization step of Arzt in view of Muller-Spanka to be two or more separated by a selected time interval as taught by Hogard, in order to promote air removal within the system (Par. 99 of Hogard). The action of periodically closing and opening the valve can “bang” the bubbles loose in the membrane exchanger (Par. 99 of Hogard). Regarding claim 17, Arzt in view of Muller-Spanka in view of Hogard discloses the invention of claim 16. The combination further discloses wherein the apparatus 1 for extracorporeal treatment of blood (Fig. 5 of Artz) comprises a blood treatment unit 5 (Fig. 5 of Artz – arterial filter 5) and the extracorporeal blood circuit 15+EC (see annotated Fig. 5 of Artz above) is coupled to the blood treatment unit 5 (Fig. 5 of Artz – filter 5 is disposed within the circuit “EC”), wherein the membrane gas exchanger 3 is located next to the blood treatment unit 5 (Fig. 5 of Artz – oxygenator 3 is to the left of the filter 5). Regarding claim 18, Arzt in view of Muller-Spanka in view of Hogard discloses the invention of claim 17. The combination further discloses wherein the membrane gas exchanger 3 (Fig. 5 of Artz) is located substantially at the same height of the blood treatment unit 5 (Fig. 5 of Artz – oxygenator 3 is substantially level with the filter 5), and wherein the method comprises placing a priming fluid waste bag 36 (Fig. 5 of Artz – collecting bag 36) below the membrane gas exchanger 3 (Fig. 5 of Artz – collecting bag 36 is below the oxygenator 3). Regarding claim 25, Arzt in view of Muller-Spanka in view of Hogard discloses the invention of claim 16. The combination further discloses wherein controlling the flow restrictor 21 (Fig. 5 of Arzt) comprises closing a clamp 21 (Fig. 5 of Arzt) placed downstream of the membrane gas exchanger 3 (Fig. 5 of Arzt, and Par. 71 of Arzt – “close the first controllable valve 21 (HC1)…”, and Par. 72 of Arzt – “an air cushion is created in the filter by the closed first controllable valve 21 (HC1) and the therefore closed venting line. The air cushion damps the flow behaviour of the incoming filling liquid”, wherein closing the valve and running the filling liquid to create an air cushion indicate a pressure build up) with respect to a flow direction of the priming fluid (Fig. 5 of Arzt – valve 21 is placed after the oxygenator 3 given the filling fluid flow direction). Regarding claim 26, Arzt in view of Muller-Spanka in view of Hogard discloses the invention of claim 25. The combination further discloses wherein said closing the clamp 21 (Fig. 5 of Arzt) placed downstream of the membrane gas exchanger 3 (Fig. 5 of Arzt) comprises repeatedly opening and closing the clamp 21 (Fig. 5 of Arzt and Par. 70 of Arzt – “The control unit, for filling and venting the patient module, is configured to close the first controllable valve 21 (HC1), which is opened after the start of the filling procedure for the venting line of the filter 5, and after the response of the upper filling level sensor 10 in the reservoir 2, in order to control the active filling of the filter 5”, and Par. 99 of Hogard – “valves of the system can be periodically actuated to open and close”) while operating the blood pump 6 (Fig. 5 of Arzt, and Par. 88-89 of Arzt – “The arrangement of reservoir 2 and blood pump 6, namely below the maximum filling level of the reservoir 2, ensures that the blood pump 6 is filled by gravity and, in this way, there is always liquid in the blood pump 6 during the venting procedure. The blood pump 6 filled with filling liquid is operated at periodic intervals at a low speed, depending on design and delivery rate”). Examiner notes that once the modification is made as discussed in claim 16, the periodic switching of valve of Hogard will be incorporated into the method of Arzt. Thus, the limitation is met. Regarding claim 31, Arzt in view of Muller-Spanka in view of Hogard discloses the invention of claim 16. The combination further discloses comprising, before feeding the priming fluid in the extracorporeal blood circuit 15+EC (see annotated Fig. 5 of Arzt above, and Par. 63 of Arzt discusses the arrangement of module 1 before feeding a priming fluid – “the components in the patient module 1 are arranged in their positions as follows…”) placing the membrane gas exchanger 3 (Fig. 5 of Arzt) close to or at the same height of the blood treatment unit 5 (Fig. 5 of Arzt – oxygenator 3 is close to and at the same height of the filter 5) and connecting a priming fluid source bag 45 (Fig. 5 of Arzt – filling liquid container 45) and a priming fluid waste bag 36 (Fig. 5 of Arzt – collecting bag 36) to the extracorporeal blood circuit 15+EC (see annotated Fig. 5 of Arzt above – the filling liquid container 45 and the collecting bag are both fluidly connected to the blood circuit 15 and the annotated EC via their attachment to reservoir 2). Regarding claim 36, Arzt in view of Muller-Spanka in view of Hogard discloses the invention of claim 16. The combination further discloses wherein filling the blood side of the membrane gas exchanger 3 (Fig. 5 of Arzt) and the second blood line section L2 (see annotated Fig. 5 of Arzt above) with priming fluid comprises filling the extracorporeal blood circuit 15+EC (see annotated Fig. 5 of Arzt above) with the priming fluid between the blood side of the membrane gas exchanger 3 (Fig. 5 of Arzt) and the second blood line section L2 (see annotated Fig. 5 of Arzt above, and Par. 89 of Arzt – “The filling liquid is conveyed from the reservoir 45 into the oxygenator 3 and onwards into the arterial filter 5”, wherein when the filling liquid reaches filter 5, it also has to fill the annotated blood line section L2) to the flow restrictor 21 (Fig. 5 of Arzt, modified by Par. 99 of Hogard, and Par. 86 of Hogard – “Pinch clamps… 180d can be configured to close the arterial and venous lines of the tubing set that connect to the user. They can also be opened and closed multiple times before, during, and after treatment to facilitate actions such as tubing set priming, discarding of priming saline,...”). Regarding claim 37, Arzt in view of Muller-Spanka in view of Hogard discloses the invention of claim 16. The combination further discloses wherein the apparatus for extracorporeal treatment of blood (Par. 21 of Arzt) comprises a blood treatment unit 5 (Fig. 5 of Artz – arterial filter 5) and the extracorporeal blood circuit 15+EC (see annotated Fig. 5 of Artz above) is coupled to the blood treatment unit 5 (Fig. 5 of Artz – filter 5 is disposed within the circuit “EC”), wherein the method comprises connecting the second blood line section L2 (see annotated Fig. 5 of Arzt above) to a patient after filling the blood side of the membrane gas exchanger 3 (Fig. 5 of Arzt) and the second blood line section L2 (see annotated Fig. 5 of Arzt above) with the priming fluid and generating the two or more transitory pressurization steps (Par. 70-72 of Arzt modified by Hogard, and Par. 63 of Arzt – “Before the system is vented, a table set 33 is attached to the venous attachment 32b and to the arterial attachment 32a, which table set 33 closes the circulation and is filled too during the venting. A patient is not attached to the circulation during the filling procedure”, and Par. 113 of Arzt – “After the system has been filled, the table set filled with the system is separated (severed) at the middle and plugged without air inclusions onto the prepared needles and perfusion commenced”). Regarding claim 39, in view of Muller-Spanka in view of Hogard discloses the invention of claim 16. The combination further discloses wherein the method comprises: stopping the blood pump 6 (Fig. 5 of Arzt, Claim 3 and claim 6 of Arzt – the filling of the reservoir via the filling liquid container is stopped”, thus no more starting of pump 6) after filling the blood side of the membrane gas exchanger 3 (Fig. 5 of Arzt) and the second blood line section L2 (see annotated Fig. 5 of Arzt) with the priming fluid and generating the two or more transitory pressurization steps (Par. 70-72 of Arzt modified by Hogard); and after stopping the blood pump 6 (Fig. 5 of Arzt), connecting the second blood line section to a patient while the blood pump 6 is stopped and the blood side of the membrane gas exchanger 3 is filled with priming fluid (Par. 112 of Arzt – “After the filling and venting procedure, the patient is attached as follows. The patient is made ready during the filling procedure, with an arterial needle being introduced into the femoral artery and with a venous needle being introduced into the femoral vein of the patient. After the system has been filled, the table set filled with the system is separated (severed) at the middle and plugged without air inclusions onto the prepared needles and perfusion commenced”). Claim 19 is rejected under 35 U.S.C. 103 as being unpatentable over Arzt in view of Muller-Spanka in view of Hogard as applied to claim 17 above, and further in view of Hochareon US 2014/0207060 A1 (previously cited, hereinafter Hochareon). Regarding claim 19, Arzt in view of Muller-Spanka in view of Hogard discloses the invention of claim 17. However, the combination does not disclose wherein the apparatus for extracorporeal treatment of blood comprises a disposable cartridge including the membrane gas exchanger, the blood treatment unit, and at least part of the extracorporeal blood circuit. Hochareon, in the same field of endeavor of extracorporeal blood apparatus (Par. 57), teaches wherein the apparatus 300 (Fig. 14 – extracorporeal blood conditioning apparatus 300) for extracorporeal treatment of blood (Par. 110 – “A schematic diagram of an extracorporeal blood conditioning apparatus of the present invention is illustrated in FIG. 14…”) comprises a disposable cartridge 310 (Fig. 14 – therapy delivery module 310, and Par. 112 – “In some embodiments, the components of therapy delivery module 310 are contained within a disposable blood circuit cartridge”) including the membrane gas exchanger 314 (Fig. 14 – oxygenation 314, and Par. 111 – “Oxygenation 314 may be provided through a conventional membrane oxygenator…”), the blood treatment unit 312 (Fig. 14-15 - external supplement 312 for supplemental drug or cell therapy, and Par. 112 – “A detailed exemplary flow diagram for therapy delivery module 310 is illustrated in FIG. 15”; Fig. 15 shows that the external supplement 312 is within the module 310), and at least part of the extracorporeal blood circuit (Par. 14-15 – arrows in these figures illustrates the circuit in which blood flows). It would have been obvious for one of ordinary skill in the art before the effective filing date of the claimed invention to have modified the apparatus for extracorporeal blood treatment of the combination to further include a disposable cartridge for the gas exchanger, blood treatment unit, and a part of the blood circuit as taught by Hochareon, in order to provide a localized therapy delivery (Par. 111 of Hochareon) and ensure adequate oxygen supply of the target tissue structure (Par. 111 of Hochareon). The localized treatment also prevents or minimize systemic side effects (Par. 14 of Hochareon). Furthermore, it is well-known within the field of extracorporeal blood treatment to have components that are in contact with blood to be disposable, so that operations can replace said components after treatment of a patient and install another module for the next patient’s treatment. Making these parts disposable allows the main housing to be reusable through multiple rounds of treatment. Claims 20-23, 29, 38, 40, 41, and 42 are rejected under 35 U.S.C. 103 as being unpatentable over Arzt in view of Muller-Spanka in view of Hogard as applied to claim 16 above, and further in view of Puppini et al. US 5,893,382 A (previously cited, hereinafter Puppini), as cited in the IDS. Regarding claim 20, Arzt in view of Muller-Spanka in view of Hogard discloses the invention of claim 16. However, the combination does not disclose wherein the selected time interval between successive pairs of the two or more transitory pressurization steps is between 10s and 100s. Puppini, in the same field of endeavor of flushing a membrane apparatus (Title), teaches wherein the selected time interval between successive pairs of the two or more transitory pressurization steps (Col. 2, line 9-12 – “the pressure waves are created by alternately opening and closing occlusion means which are arranged on the flushing circuit on the outlet side (or inlet side, respectively) of the compartment”; see annotated Fig. 2 below – a pair of two transitory pressurization steps includes two peaks and two troughs, the successive pair of two transitory pressurization starts at the next peak) is between 10s and 100s (see annotated Fig. 2 below; as seen in the annotated Fig. 2 below, the peak-to-peak period is within the marked time of 400 and 500; thus, the time interval is below 100 seconds. Furthermore, Examiner further annotated the marked time of 425, 450, and 475 to provide evidence that the annotated peak-to-peak period is indeed above 10 seconds because the interval lasts from around second 410 to over second 450, which is a duration exceeding 10 seconds; thus, the limitation is met). It would have been obvious for one of ordinary skill in the art before the effective filing date of the claimed invention to have modified the transitory pressurization step of the combination to further have pressurization interval between 10s and 100s as taught by Puppini, in order to dislodge air bubbles adhering to a wall of the blood treatment apparatus and to discharge these air bubbles in the flushing liquid (Col. 1, line 66-67 and Col. 2, line 1-3 of Puppini). Furthermore, such pressurization time interval is performed so that the upstream pressure in the pipe remains greater than the pressure the downstream pipe which prevents liquid from flowing back into the blood component unit (Col. 4, line 2-6 of Puppini). PNG media_image3.png 578 1025 media_image3.png Greyscale Annotated Fig. 2 of Puppini Regarding claim 21, Arzt in view of Muller-Spanka in view of Hogard discloses the invention of claim 16. However, the combination does not disclose wherein a maximum pressure of the priming fluid at the membrane gas exchanger during one or more of the two or more transitory pressurization step is between 100mmHg and 1000mmHg. Puppini, in the same field of endeavor of flushing a membrane apparatus (Title), teaches wherein a maximum pressure of the priming fluid (see annotated Fig. 2 above – venous pressure VP in the venous line 15; Examiner contends that the pressure PV in the venous line 15 reflects the pressure at the outlet 8 of blood compartment 3 of dialyser 2) the membrane exchanger 2 (Fig. 1 – dialyser 2) during one or more of the two or more transitory the pressurization step (Fig. 2, and Col. 4, line 54-59 – “(starting from t~350s) one can see an undulating progression of the two pressures, due to the continuing opening and closing of the valve 21. FIG. 2 also shows the course of the pressure curve VP in the venous line 15”) is between 100mmHg and 1000mmHg (see annotated Fig. 2 above – the maximum pressure recorded for PV at the outlet of dialyser 2 is above 200mmHg and less than 1000mmHg, which is within the claimed range; thus, the limitation is met). It would have been obvious for one of ordinary skill in the art before the effective filing date of the claimed invention to have modified the membrane gas exchanger of the combination to have the maximum pressure during pressurization step to be between 100mmHg and 1000mmHg as taught by Puppini, so that the upstream pressure in the pipe remains greater than the pressure the downstream pipe which prevents liquid from flowing back into the blood component unit (Col. 4, line 2-6 of Puppini). Regarding claim 22, Arzt in view of Muller-Spanka in view of Hogard discloses the invention of claim 16. However, the combination does not disclose wherein a time length of one or more of the two or more transitory pressurization steps is between 2s and 30s, wherein the time length is a function of a pressure in the blood circuit measured downstream the blood pump or is being fixed. Puppini, in the same field of endeavor of flushing a membrane apparatus (Title), teaches wherein a time length of each pressurization step (see annotated Fig. 2 above – time length of a pressurization step, which is the action of opening the valve 21 and closing the valve 21), is between 2s and 30s (see annotated Fig. 2 above – the annotated time length takes place within the annotated second 450 and second 475; one of ordinary skill in the art would have recognized that the time increment is 25 seconds, and the annotated time length does not cover the full 25 seconds for a pressurization step; thus, the time length is indeed below 30 seconds and above 2 seconds), wherein the time length of each pressurization step is a function of a pressure in the blood circuit 18 (Fig. 1 – pipe 18) measured 20 (Fig. 1 – sensor 20, and Col. 4, line 35-46 – “When the pressure prevailing in the connecting pipe 18, as measured by the sensor 20, exceeds a predetermined threshold (for example 80 mmHg), the opening of the valve 21 is controlled by the unit 55. The flushing liquid then flows into the discharge pipe 35 where the pump 36 causes it to circulate with the dialysis liquid under preparation. Thereafter, the valve 21 remains activated as a function of the pressure, but its state (open/closed) no longer depends on the absolute value of the pressure in the connecting pipe 18: it is then a function of the pressure difference ∆P…”; this implies that the time at which valve 21 is opened or closed, which is the pressurization step, depends on the measured pressure by sensor 20) downstream the blood pump 12 (Fig. 1 – arterial pump 12; sensor 20 measures pressure downstream of pump 12). It would have been obvious for one of ordinary skill in the art before the effective filing date of the claimed invention to have modified the pressurization step of the combination to further have a time length be between 2s and 30s as taught by Puppini and said time length be a function of pressure as taught by Puppini, so that the upstream pressure in the pipe remains greater than the pressure the downstream pipe which prevents liquid from flowing back into the blood component unit (Col. 4, line 2-6 of Puppini). Monitoring the pressurization step based on the measured pressure within the circuit eliminates the risk of the dialysis/priming liquid under preparation coming into contact with the blood component unit again (Col. 4, line 50-51 of Puppini). Regarding claim 23, Arzt in view of Muller-Spanka in view of Hogard in view of Puppini discloses the invention of claim 22. The combination further discloses wherein the measured pressure 20 (Fig. 1 of Puppini) is a measured return pressure (Fig. 2 of Puppini, and Col. 3, line 20-24 of Puppini – “The outlet 10 of the dialysis liquid compartment is connected to… a connecting pipe 18 equipped with a sensor 20 for pressure Pi…”, which implies that the pipe 18 and sensor 20 are disposed on a return line; thus, the limitation is met). Once the combination is made as discussed in claim 22, the method of Arzt will be incorporated the transitory pressurization step based on a function of pressure in the blood circuit measured downstream of the blood pump as taught by Puppini, which is the monitoring operation of pressure sensor 20 on a return line 18 (Fig. 1 of Puppini). Thus, the limitation is met. Regarding claim 29, Arzt in view of Muller-Spanka in view of Hogard discloses the invention of claim 16. However, the combination does not explicitly disclose wherein throughout an entire time interval after generating the two or more transitory pressurization steps and before connecting the second blood line section to a patient, a pressure in the blood circuit and in the blood side of the membrane gas exchanger is kept between 20mmHg and 400mmHg. Puppini, in the same field of endeavor of flushing a membrane apparatus (Title), teaches wherein, at the end of priming and before patient connection (see annotated Fig. 2 above – data point of venous pressure PV at the end of priming), a pressure 51 (Fig. 1 – sensor 51 for venous pressure PV) in the blood circuit 15 (Fig. 1 – venous line 15, and venous pressure PV is monitored via sensor 51) and in the blood side 3 (Fig. 1 – blood compartment 3; Examiner contends one of ordinary skill in the art would have recognized that the pressure in venous line 15 can be equivalent to the pressure at outlet 8 of the blood compartment 3 because “the outlet 8 of the blood compartment is connected to the inlet 9 of the dialysis liquid compartment by means of a venous line 15” (Col. 3, line 17-19)) of the membrane exchanger 2 (Fig. 1 – dialyser 2) is kept between 20mmHg and 400mmHg (see annotated Fig. 2 above – the data point of venous pressure PV at the end of priming is under 400mmHg and noticeably above 20mmHg as the annotated data point is above 200mmHg; thus, the limitation is met). It would have been obvious for one of ordinary skill in the art before the effective filing date of the claimed invention to have modified the method of the combination to have the pressure within the blood circuit and the blood side of the membrane gas exchanger to be between 20mmHg and 400mmHg at the end of priming as taught by Puppini, in order to facilitate the dislodging of the air bubbles, clinging to the membrane of the blood component and to the walls of the pipes, and their discharge (Col. 4, line 63-65 of Puppini). Puppini also discusses the pressurization step via activation of valve 21 (Fig. 1); therefore, one of ordinary skill in the art would have had the technological capability to realize that maintaining the pressurized environment within the extracorporeal circuit after priming will also maintain the state of being fully free of gas/air bubbles within the circuit, so that the primed circuit can be plugged to the cannulas and the patient and ready for the blood treatment, as discussed in Col. 4, last paragraph, and Col. 5, first paragraph of Puppini. Regarding claim 38, Arzt in view of Muller-Spanka in view of Hogard discloses the invention of claim 37. However, the combination does not disclose wherein the method comprises maintaining a pressure in the priming fluid in the second blood line section between the blood side of the membrane gas exchanger and the flow restrictor between 20mmHg and 400mmHg before and while connecting the second blood line section to a patient. Puppini, in the same field of endeavor of flushing a membrane apparatus (Title), teaches wherein the method comprises maintaining a pressure in the priming fluid in the second blood line section 15 (Fig. 1 – venous line 15, and venous pressure PV is monitored via sensor 51) between the blood side (Fig. 1 – blood compartment 3; Examiner contends one of ordinary skill in the art would have recognized that the pressure in venous line 15 can be equivalent to the pressure at outlet 8 of the blood compartment 3 because “the outlet 8 of the blood compartment is connected to the inlet 9 of the dialysis liquid compartment by means of a venous line 15” (Col. 3, line 17-19)) of the membrane exchanger 2 (Fig. 1 – dialyser 2) between 20mmHg and 400mmHg (see annotated Fig. 2 above – the data point of venous pressure PV at the end of priming is under 400mmHg and noticeably above 20mmHg as the annotated data point is above 200mmHg; thus, the limitation is met) before and while connecting the second blood line section to a patient (see annotated Fig. 2 above – data point of venous pressure PV right before and at the end of priming). It would have been obvious for one of ordinary skill in the art before the effective filing date of the claimed invention to have modified the maintained pressure between in the second blood line section of the combination as taught by Puppini, in order to facilitate the dislodging of the air bubbles, clinging to the membrane of the blood component and to the walls of the pipes, and their discharge (Col. 4, line 63-65 of Puppini). Puppini also discusses the pressurization step via activation of valve 21 (Fig. 1); therefore, one of ordinary skill in the art would have had the technological capability to realize that maintaining the pressurized environment within the extracorporeal circuit after priming will also maintain the state of being fully free of gas/air bubbles within the circuit, so that the primed circuit can be plugged to the cannulas and the patient and ready for the blood treatment, as discussed in Col. 4, last paragraph, and Col. 5, first paragraph of Puppini. Regarding claim 40 and claim 41, Arzt in view of Muller-Spanka in view of Hogard discloses the invention of claim 39 and claim 40, respectively. However, the combination does not disclose the method comprising maintaining a pressure in the priming fluid in the second blood line section between the blood side of the membrane gas exchanger and the flow restrictor between 20mmHg and 400mmHg before and while connecting the second blood line section to the patient. Puppini, in the same field of endeavor of flushing a membrane apparatus (Title), teaches wherein the method comprises maintaining a pressure in the priming fluid in the second blood line section 15 (Fig. 1 – venous line 15, and venous pressure PV is monitored via sensor 51) between the blood side (Fig. 1 – blood compartment 3; Examiner contends one of ordinary skill in the art would have recognized that the pressure in venous line 15 can be equivalent to the pressure at outlet 8 of the blood compartment 3 because “the outlet 8 of the blood compartment is connected to the inlet 9 of the dialysis liquid compartment by means of a venous line 15” (Col. 3, line 17-19)) of the membrane exchanger 2 (Fig. 1 – dialyser 2) between 20mmHg and 400mmHg (see annotated Fig. 2 above – the data point of venous pressure PV at the end of priming is under 400mmHg and noticeably above 20mmHg as the annotated data point is above 200mmHg; thus, the limitation is met) before and while connecting the second blood line section to a patient (see annotated Fig. 2 above – data point of venous pressure PV right before and at the end of priming). It would have been obvious for one of ordinary skill in the art before the effective filing date of the claimed invention to have modified the maintained pressure between in the second blood line section of the combination as taught by Puppini, in order to facilitate the dislodging of the air bubbles, clinging to the membrane of the blood component and to the walls of the pipes, and their discharge (Col. 4, line 63-65 of Puppini). Puppini also discusses the pressurization step via activation of valve 21 (Fig. 1); therefore, one of ordinary skill in the art would have had the technological capability to realize that maintaining the pressurized environment within the extracorporeal circuit after priming will also maintain the state of being fully free of gas/air bubbles within the circuit, so that the primed circuit can be plugged to the cannulas and the patient and ready for the blood treatment, as discussed in Col. 4, last paragraph, and Col. 5, first paragraph of Puppini. Regarding claim 42, Arzt in view of Muller-Spanka in view of Hogard discloses the invention of claim 16. However, the combination does not disclose wherein the method comprises connecting the second blood line section to a patient while maintaining a pressure in the priming fluid in the second blood line section between the blood side of the membrane gas exchanger and the flow restrictor between 20mmHg and 400mmHg. Puppini, in the same field of endeavor of flushing a membrane apparatus (Title), teaches connecting the second blood line section to a patient while maintaining a pressure in the priming fluid (see annotated Fig. 2 above – data point of venous pressure PV right before and at the end of priming) in the second blood line section 15 (Fig. 1 – venous line 15, and venous pressure PV is monitored via sensor 51) between the blood side (Fig. 1 – blood compartment 3; Examiner contends one of ordinary skill in the art would have recognized that the pressure in venous line 15 can be equivalent to the pressure at outlet 8 of the blood compartment 3 because “the outlet 8 of the blood compartment is connected to the inlet 9 of the dialysis liquid compartment by means of a venous line 15” (Col. 3, line 17-19)) of the membrane exchanger 2 (Fig. 1 – dialyser 2) between 20mmHg and 400mmHg (see annotated Fig. 2 above – the data point of venous pressure PV at the end of priming is under 400mmHg and noticeably above 20mmHg as the annotated data point is above 200mmHg; thus, the limitation is met). It would have been obvious for one of ordinary skill in the art before the effective filing date of the claimed invention to have modified the maintained pressure between in the second blood line section of the combination as taught by Puppini, in order to facilitate the dislodging of the air bubbles, clinging to the membrane of the blood component and to the walls of the pipes, and their discharge (Col. 4, line 63-65 of Puppini). Puppini also discusses the pressurization step via activation of valve 21 (Fig. 1); therefore, one of ordinary skill in the art would have had the technological capability to realize that maintaining the pressurized environment within the extracorporeal circuit after priming will also maintain the state of being fully free of gas/air bubbles within the circuit, so that the primed circuit can be plugged to the cannulas and the patient and ready for the blood treatment, as discussed in Col. 4, last paragraph, and Col. 5, first paragraph of Puppini. Claim 24 is rejected under 35 U.S.C. 103 as being unpatentable over Arzt in view Muller-Spanka in view of Hogard as applied to claim 16 above, and further evidenced by Wilt et al. US 2009/0008331 A1 (newly cited, hereinafter Wilt). Regarding claim 24, Arzt in view of Muller-Spanka in view of Hogard discloses the invention of claim 16. The combination further discloses wherein the two or more transitory pressurization steps (Par. 70-72 of Arzt modified by Par. 99 of Hogard) results in: forcing at least a portion of the priming fluid into hydrophobic pores of the gas permeable membrane (Par. 64 of Muller-Spanka) of the membrane gas exchanger 3 (Fig. 5 of Arzt, and Par. 89 – “The filling liquid is conveyed from the reservoir 45 into the oxygenator 3 and onwards into the arterial filter 5. By means of the slow filling of the filter 5 from the inlet side 50, the filter is only partially filled”, thus indicating a portion of the filling liquid has to reach the membrane), and when present, removal of micro-air bubbles accumulated at a wall of the gas permeable membrane through the gas permeable membrane (Par. 64 of Muller-Spanka) before the micro-air bubbles aggregate into macro-bubbles (Par. 60 – “The oxygenator 3 also has an attachment for a venting line 18”), whereby the apparatus for extracorporeal treatment of blood is configured to prevent formation of bubbles in the extracorporeal blood circuit (Par. 21 of Arzt – “A method is provided for preparing and venting in a device for extracorporeal blood treatment, such as a heart-lung machine”) due to the presence of the membrane gas exchanger 3 (Fig. 5 of Arzt). However, the combination does not explicitly disclose leading to a reduction of gas transfer through the gas permeable membrane. It would have been obvious for one of ordinary skill in the art before the effective filing date of the claimed invention to have had the technological capability to recognize it is well-known in the art that at least wetting the membrane prevents the gas from passing through the membrane, evidenced by Wilt (Par. 43 – “the method includes acts of urging a liquid through the dialysate flow path to the dialyzer, so as to keep the membranes wet and prevent the flow of a gas through the membranes”). Thus, the limitation “leading to a reduction of gas transfer through the gas permeable membrane” is met as a result of a portion of filling liquid of the combination going into the oxygenator 3 of Arzt. Claim 30 is rejected under 35 U.S.C. 103 as being unpatentable over Arzt in view of Muller-Spanka in view of Hogard as applied to claim 16 above, and further in view of Puppini and Bauer et al. DE 10011208 C1 (previously cited, hereinafter Bauer). Regarding claim 30, Arzt in view of Muller-Spanka in view of Hogard discloses the invention of claim 16. Arzt in view of Muller-Spanka in view of Hogard further discloses wherein throughout an entire time interval after generating the two or more transitory pressurization steps (Par. 70-72 of Arzt modified by Hogard as discussed above) and before connecting the second blood line section L2 to a patient (Par. 113 of Arzt – “After the filling and venting procedure, the patient is attached as follows…”): wherein a blood circuit portion (Fig. 5 of Arzt – the circuit portion starting from pump 6 to clamp 21, which travels from pump 6, oxygenator 3, filter 5, and ultimately valve 21) between the blood pump 6 (Fig. 5 of Arzt) and a return clamp 21 (Fig. 5 of Arzt) is isolated (Par. 112 of Arzt – ”After the filling and venting procedure… the table set filled with the system is separated (severed) at the middle…”; under broadest interpretation, “a blood circuit portion” being “isolated” is interpreted to mean the circuit being interrupted, such as being severed at the table set as discussed in Par. 112 of Arzt; before connecting to the patient and during priming, the table set 33 can be seen to be continuous and form a loop in order to prime the full extracorporeal circuit; therefore, after filling and venting procedure, the circuit portion between the pump 6 and the valve 21 is considered to be isolated, as it can no longer feed directly from arterial attachment 32a to venous attachment 32b due to the severance at table set 33), no air is allowed to enter into the blood circuit portion (Fig. 5 of Arzt – the circuit portion starting from pump 6 to clamp 21, and Par. 112 – “the table set filled with the system is separated (severed) at the middle and plugged without air inclusions onto the prepared needles…”) and a pressure regimen inside the blood circuit portion is kept constant (Par. 112 of Arzt – “After the system has been filled, the table set filled with the system is separated (severed) at the middle and plugged without air inclusions onto the prepared needles and perfusion commenced”; which implies that once the deaeration of the circuit portion has been completed, said circuit portion is kept the same with the only change being the needles attachment at the table set to the patient). However, the combination does not disclose a pressure in the blood circuit and in the blood side of the membrane gas exchanger is kept between 20mmHg and 400mmHg; the blood pump is stopped while a clamp placed on a blood return line downstream of the membrane gas exchanger is kept closed. Puppini, in the same field of endeavor of flushing a membrane apparatus (Title), teaches wherein at the end of priming and before patient connection (see annotated Fig. 2 above – data point of venous pressure PV at the end of priming): a pressure 51 (Fig. 1 – sensor 51 for venous pressure PV) in the blood circuit 15 (Fig. 1 – venous line 15, and venous pressure PV is monitored via sensor 51) and in the blood side 3 (Fig. 1 – blood compartment 3; Examiner contends one of ordinary skill in the art would have recognized that the pressure in venous line 15 can be equivalent to the pressure at outlet 8 of the blood compartment 3 because “the outlet 8 of the blood compartment is connected to the inlet 9 of the dialysis liquid compartment by means of a venous line 15” (Col. 3, line 17-19)) of the membrane exchanger 2 (Fig. 1 – dialyser 2) is kept between 20mmHg and 400mmHg (see annotated Fig. 2 above – the data point of venous pressure PV at the end of priming is under 400mmHg and noticeably above 20mmHg as the annotated data point is above 200mmHg; thus, the limitation is met). Bauer, in the same field of endeavor of filling/rinsing method (Par. 1 in the provided translation), teaches wherein at the end of priming and before patient connection (Par. 47 in the provided translation – “the hemodialysis machine is ready for hemodialysis treatment”): the blood pump 53 (Fig. 1 – blood pump 53) is stopped (Par. 47 in the provided translation – “with the blood pump 53 stopped”) while a clamp 63 (Fig. 1 – clamp 63) placed on a blood return line 62 (Fig. 1 – withdrawal line 62) downstream of the membrane exchanger 30 (Fig. 1 – hemodialyzer 30; clamp 63 is downstream of hemodialyzer 30 according to the arrows direction) is kept closed (Par. 47 in the provided translation – “the clamp 63 in the withdrawal line 62 closed…”). It would have been obvious for one of ordinary skill in the art before the effective filing date of the claimed invention to have modified the method of the combination to have the pressure within the blood circuit and the blood side of the membrane gas exchanger to be between 20mmHg and 400mmHg at the end of priming as taught by Puppini, in order to facilitate the dislodging of the air bubbles, clinging to the membrane of the blood component and to the walls of the pipes, and their discharge (Col. 4, line 63-65 of Puppini). Puppini also discusses the pressurization step via activation of valve 21 (Fig. 1); therefore, one of ordinary skill in the art would have had the technological capability to realize that maintaining the pressurized environment within the extracorporeal circuit after priming will also maintain the state of being fully free of gas/air bubbles within the circuit, so that the primed circuit can be plugged to the cannulas and the patient and ready for the blood treatment, as discussed in Col. 4, last paragraph, and Col. 5, first paragraph of Puppini. It would have been obvious for one of ordinary skill in the art before the effective filing date of the claimed invention to have modified the method of the combination to further have the blood pump and downstream clamp be closed at the end of priming as taught by Bauer, in order to maintain an extracorporeal blood circuit filled with sterile fluid (Par. 47 in the provided translation of Bauer) so that the machine is ready for treatment (Par. 47 in the provided translation of Bauer). Furthermore, one of ordinary skill in the art would have had the technological capability to recognize that once the circuit has been pressurized and purged, releasing it to atmospheric environment might once again expose the circuit to air bubbles; thus, sealing off the circuit as taught by Bauer would prevent further air bubbles. Conclusion The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Kim et al. US 2003/0163077 A1 teaches chucking of hemodialyzing apparatus by opening and closing a valve to remove accumulated air. Any inquiry concerning this communication or earlier communications from the examiner should be directed to QUYNH DAO LE whose telephone number is (571)272-7198. The examiner can normally be reached Monday - Friday 8:30 am - 5:30 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sarah Al-Hashimi can be reached at (571) 272-7159. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /QUYNH DAO LE/Examiner, Art Unit 3781 /SARAH AL HASHIMI/Supervisory Patent Examiner, Art Unit 3781
Read full office action

Prosecution Timeline

Feb 14, 2022
Application Filed
Dec 19, 2024
Non-Final Rejection mailed — §103, §112
May 19, 2025
Response Filed
Aug 20, 2025
Final Rejection mailed — §103, §112
Jan 20, 2026
Request for Continued Examination
Feb 19, 2026
Response after Non-Final Action
Sep 30, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12758251
Bi-Modal Intraocular Shunt Inserter
4y 2m to grant Granted Oct 13, 2026
Patent 12721938
METHOD FOR FILLING A MEMBRANE
5y 1m to grant Granted Sep 01, 2026
Patent 12521471
BLOOD BAG SYSTEM AND MANUFACTURING METHOD THEREFOR
3y 11m to grant Granted Jan 13, 2026
Patent 12496236
ABSORBENT ARTICLE
4y 6m to grant Granted Dec 16, 2025
Patent 12433987
PHOTODYNAMIC THERAPY DEVICE
4y 1m to grant Granted Oct 07, 2025
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
33%
Grant Probability
45%
With Interview (+12.1%)
3y 6m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 48 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month